HELP · Cybin Inc. Common Stock

The appointment of Dr. Ken Kramer as Senior Vice President, Medical Affairs represents a strategic reinforcement of Helus Pharma’s clinical and regulatory infrastructure at a critical inflection point: HLP003 is in Phase 3 development for major depressive disorder with FDA Breakthrough Therapy Designation, and HLP004 is in Phase 2 for generalized anxiety disorder. Dr. Kramer’s background — including leadership of the first new schizophrenia treatment launch in over 70 years at Bristol Myers Squibb and medical affairs expansion during Karuna’s acquisition — directly addresses investor concerns around execution risk in neuropsychiatry development. His academic foundation in neuropharmacology and prior roles at AbbVie and in academic psychiatry further validate domain-specific credibility. While the filing does not disclose compensation terms or reporting lines, the CEO’s statement explicitly ties the hire to scaling medical capabilities and translating science into engagement with providers and payors — suggesting preparation for upcoming data readouts, regulatory interactions, and potential commercial planning. As a 6-K filed by a foreign private issuer, this event carries medium materiality: it strengthens operational readiness but does not alter financial position, pipeline timelines, or regulatory status as disclosed.